S&P 500   3,849.62
DOW   30,937.04
QQQ   328.59
S&P 500   3,849.62
DOW   30,937.04
QQQ   328.59
S&P 500   3,849.62
DOW   30,937.04
QQQ   328.59
S&P 500   3,849.62
DOW   30,937.04
QQQ   328.59
Log in

BELLUS Health Inc. (BLU.TO) Stock Forecast, Price & News

-0.10 (-2.09 %)
(As of 01/26/2021 12:00 AM ET)
Today's Range
Now: C$4.68
50-Day Range
MA: C$4.17
52-Week Range
Now: C$4.68
Volume157,278 shs
Average Volume298,155 shs
Market CapitalizationC$366.62 million
P/E RatioN/A
Dividend YieldN/A
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of chronic cough and other hypersensitization disorders. Its lead drug candidate includes BLU-5937, an oral small molecule antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of chronic cough and chronic pruritus. BELLUS Health Inc. was founded in 1993 and is headquartered in Laval, Canada.


Overall MarketRank

0.48 out of 5 stars

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Biotechnology
Year FoundedN/A



Sales & Book Value

Annual SalesC$17,269.00
Price / Sales21,229.79
Cash FlowC$0.86 per share
Book ValueC$1.92 per share



Market CapC$366.62 million
Next Earnings Date2/25/2021 (Estimated)
OptionableNot Optionable
-0.10 (-2.09 %)
(As of 01/26/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BLU News and Ratings via Email

Sign-up to receive the latest news and ratings for BLU and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

BELLUS Health Inc. (BLU.TO) (TSE:BLU) Frequently Asked Questions

How has BELLUS Health Inc. (BLU.TO)'s stock price been impacted by Coronavirus?

BELLUS Health Inc. (BLU.TO)'s stock was trading at C$13.01 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, BLU shares have decreased by 64.0% and is now trading at C$4.68.
View which stocks have been most impacted by COVID-19

Is BELLUS Health Inc. (BLU.TO) a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BELLUS Health Inc. (BLU.TO) in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BELLUS Health Inc. (BLU.TO) stock.
View analyst ratings for BELLUS Health Inc. (BLU.TO)
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than BELLUS Health Inc. (BLU.TO)?

Wall Street analysts have given BELLUS Health Inc. (BLU.TO) a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but BELLUS Health Inc. (BLU.TO) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is BELLUS Health Inc. (BLU.TO)'s next earnings date?

BELLUS Health Inc. (BLU.TO) is scheduled to release its next quarterly earnings announcement on Thursday, February 25th 2021.
View our earnings forecast for BELLUS Health Inc. (BLU.TO)

How were BELLUS Health Inc. (BLU.TO)'s earnings last quarter?

BELLUS Health Inc. (BLU.TO) (TSE:BLU) issued its quarterly earnings data on Thursday, November, 12th. The company reported ($0.12) EPS for the quarter, beating analysts' consensus estimates of ($0.21) by $0.09.
View BELLUS Health Inc. (BLU.TO)'s earnings history

Who are some of BELLUS Health Inc. (BLU.TO)'s key competitors?

What other stocks do shareholders of BELLUS Health Inc. (BLU.TO) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BELLUS Health Inc. (BLU.TO) investors own include Exxon Mobil (XOM), Bombardier (BDRBF), AbbVie (ABBV), Energy Transfer (ET), General Electric (GE), The Coca-Cola (KO), Alexion Pharmaceuticals (ALXN), Advanced Micro Devices (AMD), The Boeing (BA) and The Walt Disney (DIS).

Who are BELLUS Health Inc. (BLU.TO)'s key executives?

BELLUS Health Inc. (BLU.TO)'s management team includes the following people:
  • Mr. Roberto Francesco Bellini, Pres, CEO & Director (Age 40, Pay $661.99k)
  • Mr. François Desjardins C.A., CPA, CPA, CA, VP of Fin. (Age 57, Pay $298.12k)
  • Dr. Denis Garceau, Sr. VP of Drug Devel. (Age 63, Pay $469.3k)
  • Dr. Catherine M. Bonuccelli, Chief Medical Officer (Age 62, Pay $473.7k)
  • Mr. Tony Matzouranis, VP of Bus. Devel. (Age 47, Pay $304.5k)
  • Mr. Ramzi Benamar, Chief Financial Officer (Age 47)
  • Mr. Daniel Matthews, Director of Investor Relations & Communications
  • Mr. Sébastien Roy, Corp. Sec. (Age 44)

What is BELLUS Health Inc. (BLU.TO)'s stock symbol?

BELLUS Health Inc. (BLU.TO) trades on the Toronto Stock Exchange (TSX) under the ticker symbol "BLU."

How do I buy shares of BELLUS Health Inc. (BLU.TO)?

Shares of BLU and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

What is BELLUS Health Inc. (BLU.TO)'s stock price today?

One share of BLU stock can currently be purchased for approximately C$4.68.

How big of a company is BELLUS Health Inc. (BLU.TO)?

BELLUS Health Inc. (BLU.TO) has a market capitalization of C$366.62 million and generates C$17,269.00 in revenue each year. BELLUS Health Inc. (BLU.TO) employs 17 workers across the globe.

What is BELLUS Health Inc. (BLU.TO)'s official website?

The official website for BELLUS Health Inc. (BLU.TO) is www.bellushealth.com.

How can I contact BELLUS Health Inc. (BLU.TO)?

BELLUS Health Inc. (BLU.TO)'s mailing address is 9-275 Armand-Frappier Blvd, LAVAL, QC H7V 4A7, Canada. The company can be reached via phone at +1-450-6804500.

This page was last updated on 1/27/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.